Cargando…
Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
Molecular mechanism underlying glucagon‐like peptide‐1 exertion of cardioprotective effects in glucagon‐like peptide‐1 receptor‐dependent and ‐independent manners. Glucagon‐like peptide‐1 (28‐36a) enters coronary artery endothelial cells through macropinocytosis and binds to mitochondrial trifunctio...
Autores principales: | Liu, Yangyang, Kubota, Sodai, Iizuka, Katsumi, Yabe, Daisuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610112/ https://www.ncbi.nlm.nih.gov/pubmed/32428993 http://dx.doi.org/10.1111/jdi.13302 |
Ejemplares similares
-
Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?
por: Kubota, Sodai, et al.
Publicado: (2021) -
Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012) -
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
por: Taing, Meng-Wong, et al.
Publicado: (2014) -
GLP-1(28-36)amide, a Long Ignored Peptide Revisited
por: Zhou, Bilan, et al.
Publicado: (2014) -
Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)